ストックスクリーナーアプリを入手
0.611
1.63%
0.0098
アフターアワーズ：
.62
0.009
+1.47%
前日終値:
$0.6012
開ける：
$0.6012
24時間の取引高:
202.50K
Relative Volume:
0.17
時価総額：
$4.53M
収益：
-
当期純損益:
$-6.07M
株価収益率:
-0.1057
EPS:
-5.78
ネットキャッシュフロー:
$-7.34M
1週間 パフォーマンス:
-11.39%
1か月 パフォーマンス:
-13.94%
6か月 パフォーマンス:
-40.10%
1年 パフォーマンス:
-59.27%
1日の値動き範囲:
$0.5963
$0.6256
1週間の範囲:
$0.5704
$0.6969
52週間の値動き範囲:
$0.5704
$3.00
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
名前
Adial Pharmaceuticals Inc
セクター
電話
434-422-9800
住所
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
ADIL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.611 | 4.53M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
| 2018-10-30 | 開始されました | Maxim Group | Buy |
| 2018-10-11 | 開始されました | Dawson James | Buy |
Adial Pharmaceuticals Inc (ADIL) 最新ニュース
Adial Pharmaceuticals (ADIL) Projected to Post Quarterly Earnings on Tuesday - Defense World
FDA to Review Adial’s Phase 3 Trial Plan for AUD Treatment - Investing.com Nigeria
FDA Has Granted Request for End of Phase 2 Meeting to Discuss Alcohol Use Disorder Treatment, AD04 - Psychiatric Times
FDA to Review Adial’s Phase 3 Trial Plan for AUD Treatment By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Granted End Of Phase 2 Meeting From FDA - marketscreener.com
EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program - AOL.com
Adial Pharmaceuticals (ADIL) Receives FDA Green Light for Phase 3 Meeting | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration - The Manila Times
Renaissance Technologies LLC Purchases New Stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) - Defense World
Richmond InnoAdial Pharmaceuticals raises $2.75M - The Business Journals
Biotech Alert: Searches spiking for these stocks today - TipRanks
ADIL: Adial Pharmaceuticals Boosts Patent Portfolio with New Approval | ADIL Stock News - GuruFocus
Geode Capital Management LLC Grows Stock Holdings in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) - Defense World
Adial Pharmaceuticals secures $2.75 million through warrant exercise By Investing.com - Investing.com Nigeria
Press Release Distribution & PR Platform - ACCESS Newswire
Adial Pharmaceuticals secures $2.75 million through warrant exercise - Investing.com
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds - GlobeNewswire
Healthcare Investor Commits $2.75M to Adial Pharmaceuticals Addiction Treatment Pipeline - Stock Titan
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring - Asianet Newsable
Adial Pharmaceuticals Inc: Rising -76.71% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
How will Adial Pharmaceuticals Inc’s (ADIL) earnings compare to estimates this quarter? - uspostnews.com
Adial Pharmaceuticals (ADIL) Secures Patent for Novel Addiction Treatment Method | ADIL Stock News - GuruFocus
Adial Pharmaceuticals secures patent for addiction treatment - Investing.com
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders - GlobeNewswire
Revolutionary Patent Links Genetic Markers to Personalized Addiction Treatment Success - Stock Titan
EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders - Yahoo
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Pharmaceuticals CEO Weighs in on the Alcohol Pandemic and Drunk Driving Over the Holidays; FOX31 Denver's Shaul Turner Interviews Bill Stilley - ACCESS Newswire
Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial - ACCESS Newswire
Adial Pharmaceuticals Files Post-Effective Amendments to Registration Statements For Outstanding Shares Underlying Existing Warrants and Shelf Registration Statement to Provide Financial Flexibility - ACCESS Newswire
Adial Pharma stock hits 52-week low at $0.6 amid market challenges - Investing.com Australia
Adial Pharma stock hits 52-week low at $0.6 amid market challenges By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D. - ACCESS Newswire
Adial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder - ACCESS Newswire
Alcohol Use Disorder Treatment Market: Discover the Best - openPR.com
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 19.8% in March - Defense World
Adial Pharmaceuticals Appoints Tony Goodman as COO - TipRanks
Adial Pharmaceuticals appoints new COO Tony Goodman - Investing.com
Litchfield Hills Research Predicts ADIL Q1 Earnings - Defense World
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Grows By 610.2% - Defense World
Adial Pharma stock hits 52-week low at $0.69 amid market challenges - Investing.com
Brookline Capital Management Estimates ADIL Q1 Earnings - Defense World
Rodman & Renshaw maintains Adial stock Buy rating, $8 target By Investing.com - Investing.com Australia
Rodman & Renshaw maintains Adial stock Buy rating, $8 target - Investing.com India
Adial Pharma stock hits 52-week low at $0.71 amid market challenges - Investing.com
Adial Pharma stock hits 52-week low at $0.71 amid market challenges By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update - GlobeNewswire
ADIAL PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Adial Pharmaceuticals Inc (ADIL) 財務データ
収益
当期純利益
現金流量
EPS
4.10%
大文字化:
|
ボリューム (24 時間):